



# Resource impact statement

Resource impact

Published: 28 October 2021

[www.nice.org.uk](http://www.nice.org.uk)

## No significant resource impact is anticipated

NICE has recommended apalutamide plus androgen deprivation therapy (ADT), within its marketing authorisation, as an option for treating hormone-relapsed non-metastatic prostate cancer that is at high risk of metastasising in adults. High risk is defined as a blood prostate specific antigen (PSA) level that has doubled in 10 months or less on continuous ADT. It is recommended only if the company provides apalutamide according to the commercial arrangement.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the technology is a further treatment option which is available at a similar price to current treatment options and the eligible population is small. Around 700 people are expected to be eligible for treatment each year.

Apalutamide has a discount that is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.